依达拉奉联合法舒地尔应用于急性脑梗死患者的治疗效果观察

Effect of Edaravone combined with Fasudil Hydrochloride for the Patients with Acute Cerebral Infarction

目的:观察依达拉奉联合法舒地尔应用于急性脑梗死(acute cerebral infarction,ACI)患者的治疗效果及其安全性。方法:选取我院2011年1月-2014年1月收治的急性脑梗死患者96例,随机分为观察组和对照组,每组48例。观察组患者应用盐酸法舒地尔联合依达拉奉静脉滴注,对照组患者单独应用盐酸法舒地尔静脉滴注射。观察并比较两组患者的治疗效果、神经功能缺损的变化情况及不良反应的发生情况等。结果:治疗前,两组患者NIHSS、BI评分及NSE水平比较无明显差异(P<0.05);治疗后,两组患者NIHSS、BI评分及NSE水平均较治疗前明显改善,且观察组改善更明显,差异具有统计学意义(P<0.05);观察组治疗总有效率高于对照组,差异具有统计学意义(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论:依达拉奉联合法舒地尔对急性脑梗死患者的临床效果显著,不仅可以改善患者的神经功能缺损情况,而且能够改善NSE水平,值得临床推广应用。

Objective： To observe the clinical effect of edaravone combine with fasudil hydrochloride on the treamaent of the acute cerebral infarction. Methods： 96 cases with acute cerebral infarction who were treated in our hospital fxom January 2011 to January 2014 were selected and randomly divided into the observation group and the control group, with 48 cases in each group. The patients in the observation group were received the hydrochloric acid combined with edaravone, while the patients in the control group were only received the hydrochloric. Then the nerve fimction defect changes and adverse reactions after the treatment in the two groups were observed and compared. Results： Before the treatment, there was no statistically significant difference about the NIHSS, BI score and NSE levels in the two groups （P〉0.05）; After the treatment, the symptomps improved in the two groups, and the observation group was better than that of the control group, and the differences were statistically significant （P〈0.05）; The clinical efficacy rate of the observation group was higher than that of the control group with statistically significant difference （P〈0.05）; There was no statistically significant difference about the incidence of the adverse reactions after the treatment between the two groups （P〉0.05）. Conclusion： Fasudil hydrochloride combine with edaravone on the treatment of acute cerebral infarction can improve the nerve function and the level of NSE of patients, which is worthy of clinical promotion and application.